OptiBiotix Health PLC SlimBiome(R) contract manufacturing agreement (4610I)
April 02 2020 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 4610I
OptiBiotix Health PLC
02 April 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
SlimBiome(R) contract manufacturing agreement with Fipros
A/S
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has
entered into a contract manufacturing agreement with Fipros A/S
("Fipros") in Denmark.
Fipros ( www.fipros.dk ) is a Danish contract manufacturer
founded in 1992 with operations in Sweden and Denmark. The terms of
the agreement grant Fipros the rights to utilise OptiBiotix's IP to
manufacture SlimBiome(R) under licence.
This is another strategic step by OptiBiotix to derisk its
supply chain in case of a hard Brexit as the agreement creates a
source of supply located within the European Union to support the
commercial launch of SlimBiome(R) in Poland (RNS: 6 December 2019)
and Germany (RNS: 19 December 2019).
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division , c o mmented: "We are very pleased to work with Fipros to
manufacture SlimBiome (R) within the European Union. The agreement
is key as it helps us lower the cost of trade, support our existing
and future European distributors and build contingency in the
supply chain which is a key requirement from large commercial
partners who do not want to be single-sourced. In addition, Fipros
has a Certification and Accreditation Administration of the
People's Republic of China (CNCA) registration thus enabling us to
fast track future possible exports to China."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRIBMITMTJMBLM
(END) Dow Jones Newswires
April 02, 2020 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024